Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Large Drop in Short Interest

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a large drop in short interest in the month of August. As of August 14th, there was short interest totaling 20,858 shares, a drop of 86.5% from the July 30th total of 154,671 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 2,242,858 shares, the days-to-cover ratio is currently 0.0 days.

Azitra Price Performance

AZTR stock traded up $0.01 during trading on Thursday, reaching $0.19. 2,401,503 shares of the stock traded hands, compared to its average volume of 9,635,426. The business’s 50 day moving average price is $0.15 and its 200-day moving average price is $0.19. Azitra has a 52-week low of $0.10 and a 52-week high of $1.09.

Azitra (NYSEAMERICAN:AZTR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). As a group, research analysts predict that Azitra will post -0.25 EPS for the current year.

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.